FUTURE WEBINAR - 2026, Tuesday August 25th - “Co-creating sustainable healthcare through patient involvement: innovation, risk, and regulatory perspectives”
CLICK HERE TO REGISTER
ABSTRACT
Sustainable, effective, and scalable in silico solutions depend on alignment with patient needs, expectations, and lived experience. However, patient and public involvement (PPI) remains inconsistently implemented across technology development, commercialisation, and regulatory pathways, thereby limiting opportunities to improve technology uptake, trust, long-term impact, and regulatory readiness.
Embedding PPI early and systematically across innovation lifecycles offers a strategic opportunity to improve decision-making, accelerate adoption, reduce uncertainty, and strengthen benefit-risk evaluation. Patient experience data, preference studies, and patient-informed evidence generation increasingly receive recognition for their potential to inform regulatory decision-making, e.g., as reflected by recent EMA consultations. However, many organisations remain uncertain on how to systematically capture and operationalise the patient voice to inform in silico innovation. Failure to engage proactively risks misalignment with end-user needs, reduced technology uptake, and delayed readiness for emerging regulatory expectations.
The Avicenna Alliance PPI Task Force, the first internationally coordinated initiative dedicated to PPI in in silico medicine, advances a structured approach to integrating patient perspectives into innovation, policy, and regulatory thinking. Activities include the co-development of PPI frameworks and roadmaps, multi-stakeholder engagement models, awareness and trust-building activities, policy contributions, and practical implementation resources, including a multilingual plain-language glossary for in silico medicine. The task force actively contributes to regulatory dialogue through responses to EMA open consultations, including on patient preference studies and patient experience data, positioning Avicenna Alliance members to help shape emerging regulatory thinking.
This session highlights how PPI can become a strategic asset for accelerating innovation, reducing translational and regulatory risk, strengthening technology adoption, and informing regulatory decision-making. It further outlines practical opportunities to implement PPI and engage with the Avicenna Alliance PPI Task Force to help shape the future of patient-centred in silicoinnovation while generating tangible business, regulatory, and societal value.
